Strengthening Global Market Access Readiness Through Early Payer & HTA Planning
Introduction: A global biopharma company preparing to advance towards asset commercialisation approached Thelansis with a clear priority that they wanted to enter multiple markets with confidence tha ...
Mergers & Acquisitions in Pharma — What 2025 taught us and where the momentum is heading in 2026
2025 almost felt like pharma pressed a reset button on dealmaking. Money moved in patches, a handful of blockbuster deals grabbed headlines and reshaped competitive positions, while the broader market ...